Administration of the bisphosphonates drugs which contain nitrogen (such as zoledronate), in patients of osteoporosis and hypercalcemiain malignancies, lead to enhanced intracellular IPP levels via inhibition of one of the mevalonate pathway enzymes i.e., farnesyl diphosphate synthase. The gene discussed is FDPS; the disease is osteoporosis.